NICE rejects J&J’s Spravato for treatment-resistant depressionThe UK healthcare cost-effectiveness agency has said it will not recommend funding for Johnson & Johnson’s antidepressant nasal Share XNICE rejects J&J’s Spravato for treatment-resistant depressionhttps://pharmaphorum.com/news/nice-rejects-jjs-spravato-for-treatment-resistant-depression/
Roche files Tecentriq, Avastin combo as a liver cancer therapyRoche has filed for approval of a two-drug combination of its Tecentriq and Avastin drugs in previously-untreated hepatocellular Share XRoche files Tecentriq, Avastin combo as a liver cancer therapyhttps://pharmaphorum.com/news/roche-files-tecentriq-avastin-combo-as-a-liver-cancer-therapy/
Ipsen craters as pricey rare disease drug is put on hold againFrench drugmaker Ipsen’s big-ticket investment in rare bone disease drug palovarotene is looking increasingly like a poor deal, Share XIpsen craters as pricey rare disease drug is put on hold againhttps://pharmaphorum.com/news/ipsen-craters-as-pricey-rare-disease-drug-is-put-on-hold-again/
Despite benefits, blockchain adoption is slow in life sciences, says reportWidespread adoption of blockchain could add $3 billion-worth of value to life sciences companies by 2025, but adoption Share XDespite benefits, blockchain adoption is slow in life sciences, says reporthttps://pharmaphorum.com/news/despite-benefits-blockchain-adoption-is-slow-in-life-sciences-says-report/
Tumour-agnostic drugs ‘game-changing’, says NICE as it rejects one from BayerThe UK’s cost-effectiveness agency has said it can’t recommend Bayer’s tumour-agnostic drug Vitrakvi for routine use on the Share XTumour-agnostic drugs ‘game-changing’, says NICE as it rejects one from Bayerhttps://pharmaphorum.com/news/tumour-agnostic-drugs-game-changing-says-nice-as-it-rejects-one-from-bayer/
Nektar pulls pain drug after bruising FDA panel meetingNektar Therapeutics has opted to withdraw its marketing application for new opioid painkiller oxycodegol after an FDA advisory Share XNektar pulls pain drug after bruising FDA panel meetinghttps://pharmaphorum.com/news/nektar-pulls-pain-drug-after-bruising-fda-panel-meeting/
Oviva raises $21m for digital tool to help reverse diabetesSwiss digital therapy specialist Oviva has raised $21 million in second-round financing to help expand the use of Share XOviva raises $21m for digital tool to help reverse diabeteshttps://pharmaphorum.com/news/oviva-raises-21m-for-digital-tool-to-help-reverse-diabetes/
ViiV’s two-drug HIV therapy Dovato gets Japanese approvalOne of ViiV Healthcare’s two-drug HIV therapies – Dovato – has been approved in Japan, providing a new Share XViiV’s two-drug HIV therapy Dovato gets Japanese approvalhttps://pharmaphorum.com/news/viivs-two-drug-hiv-therapy-dovato-gets-japanese-approval/
MorphoSys gets $750m from Incyte for anti-CD19 cancer drugIncyte has agreed a deal with Germany’s MorphoSys to license an antibody that could be an alternative to Share XMorphoSys gets $750m from Incyte for anti-CD19 cancer drughttps://pharmaphorum.com/news/morphosys-gets-750m-from-incyte-for-anti-cd19-cancer-drug/
